Piper Sandler analyst Crispin Love maintained a Hold rating on Enfusion (ENFN – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $9.18.
According to TipRanks, Love is a 4-star analyst with an average return of 8.7% and a 64.29% success rate. Love covers the Real Estate sector, focusing on stocks such as AGNC Investment, Annaly Capital, and Ellington Financial.
The word on The Street in general, suggests a Hold analyst consensus rating for Enfusion with a $9.60 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ENFN market cap is currently $1.17B and has a P/E ratio of 189.67.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ENFN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enfusion (ENFN) Company Description:
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Read More on ENFN:
